{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:53:35Z","timestamp":1785372815246,"version":"3.55.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc."},{"DOI":"10.13039\/100020124","name":"Seagen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,2,19]]},"DOI":"10.1080\/14796694.2024.2445498","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:23:26Z","timestamp":1736497406000},"page":"569-578","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain"],"prefix":"10.1080","volume":"21","author":[{"given":"Ahmet","family":"Hasaligil","sequence":"first","affiliation":[{"name":"Astellas Pharma Europe Ltd","place":["Addlestone, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Munro","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd","place":["Addlestone, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-8794","authenticated-orcid":false,"given":"Torsten","family":"Strunz-McKendry","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd","place":["Addlestone, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang-Silvanto","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd","place":["Addlestone, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Milloy","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Adelphi Real World","place":["Bollington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.614"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19199-z"},{"key":"e_1_3_8_8_1","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation): Padcev (enfortumab vedotin). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-padcev_en.pdf"},{"issue":"1","key":"e_1_3_8_9_1","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15.","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0573"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0271-0"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010192"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170149"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20285"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010131"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211021667"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-190252"},{"key":"e_1_3_8_23_1","unstructured":"Astellas Pharma Inc. Japan\u2019s MHLW approves PADCEV\u00ae (enfortumab vedotin) for advanced urothelial cancer. Press release. Available from: https:\/\/newsroom.astellas.us\/2021-09-27-Japans-MHLW-Approves-PADCEV-R-enfortumab-vedotin-for-Advanced-Urothelial-Cancer"},{"issue":"1","key":"e_1_3_8_24_1","article-title":"CADTH reimbursement recommendation enfortumab vedotin (padcev)","volume":"2","author":"Canada\u2019s Drug and Health Technology Agency (CADTH)","year":"2022","unstructured":"Canada\u2019s Drug and Health Technology Agency (CADTH). CADTH reimbursement recommendation enfortumab vedotin (padcev). Can J Health Technol. 2022;2(1).","journal-title":"Can J Health Technol"},{"key":"e_1_3_8_25_1","volume-title":"Highlights of Padcev prescribing information","author":"Astellas Pharma Inc","unstructured":"Astellas Pharma Inc. Highlights of Padcev prescribing information. Available from: https:\/\/astellas.us\/docs\/padcev_label.pdf."},{"key":"e_1_3_8_26_1","volume-title":"Padcev","author":"European Medicines Agency","unstructured":"European Medicines Agency. Padcev. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/padcev"},{"key":"e_1_3_8_27_1","unstructured":"European Association of Urology (EAU). EAU guidelines on muscle-invasive and metastatic bladder cancer. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Muscle-Invasive-And-Metastatic-Bladder-Cancer-2022.pdf"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.11.014"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.09.010"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_8_31_1","unstructured":"Food and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer"},{"key":"e_1_3_8_32_1","unstructured":"European Medicines Agency. Enfortumab vedotin. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/padcev"},{"key":"e_1_3_8_33_1","unstructured":"European Medicines Agency. Summary of opinion (post authorisation): Bavencio (avelumab). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-bavencio-ii-18_en.pdf"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72820-y"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2445498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:41:21Z","timestamp":1741099281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2445498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,2,19]]}},"alternative-id":["10.1080\/14796694.2024.2445498"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2445498","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}